Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas
- 414 Downloads
We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. (J Clin Oncol 25:2601–2606, 2007). Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n = 22; 95% CI, 7.3–12.8 months) and 9.6 months (n = 19; 95% CI, 6.9–11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n = 11; 95% CI, 4.4–11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n = 129; 95% CI, 3.6–5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.
KeywordsBNCT BPA–PET GBM MG RPA
This work was partly supported by Grants-in-Aid for Scientific Research (B) (16390422 and 19390385) from the Japanese Ministry of Education, Science and Culture, by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan to S–I.M. (P·I., Hideki Matsui) and by the Regional Science Promotion Program of the Japan Science and Technology Corporation, as well as by the “Second-term Comprehensive 10-Year Strategy for Cancer Control” of the Ministry of Health, Labor, and Welfare of Japan to S–I.M. This work was also supported in part by the Takeda Science Foundation for Osaka Medical College, by a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (12217065) to K. O., and by Grants-in-Aid for Scientific Research by young researchers (B) (18791030) from the Japanese Ministry of Education, Science, and Culture to S. K. The top two authors contributed equally in this study as primary co-investigators.
- 2.Miyatake S, Kawabata S, Kajimoto Y et al (2005) Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg 103:1000–1009PubMedCrossRefGoogle Scholar
- 7.Kawabata S, Miyatake S, Kuroiwa T et al Boron neutron capture therapy for newly diagnosed glioblastoma. J Rad Res (in press)Google Scholar
- 8.Carson KA, Grossman SA, Fisher JD et al (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25:2601–2606. doi: 10.1200/JCO.2006.08.1661 PubMedCrossRefGoogle Scholar
- 11.Sakurai Y, Ono K, Miyatake S et al (2006) Improvement effect on the depth-dose distribution by CSF drainage and air infusion of a tumour-removed cavity in boron neutron capture therapy for malignant brain tumours. Phys Med Biol 51:1173–1183. doi: 10.1088/0031-9155/51/5/009 PubMedCrossRefGoogle Scholar